Evidence map›Paper›PMID 37351453›Full record

ArticleOpen forum infectious diseases2023

Association of Self-reported Systemic Reactions Following SARS-CoV-2 Vaccination With Immunological Response in the Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines (ENFORCE).

Wendy P Bannister, Dorthe Raben, Palle Valentiner-Branth, Martin Tolstrup, Lykke Larsen, Britta Tarp, Mette Brouw Iversen, Ole Schmeltz Søgaard, Sisse Rye Ostrowski, Nina Breinholt Stærke and 17 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Wendy P BannisterCentre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-4780-3364
Dorthe RabenCentre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Palle Valentiner-BranthDepartment of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
Martin TolstrupDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Lykke LarsenDepartment of Infectious Diseases, Odense University Hospital, Odense, Denmark.
Britta TarpDiagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.
Mette Brouw IversenDepartment of Medicine, Zealand University Hospital, Roskilde, Denmark.
Ole Schmeltz SøgaardDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Sisse Rye OstrowskiDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Nina Breinholt StærkeDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Marie Louise JakobsenCentre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Susan Olaf LindvigDepartment of Infectious Diseases, Odense University Hospital, Odense, Denmark.
Maria Ruwald JuhlDepartment of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark.
Isik Somuncu JohansenDepartment of Infectious Diseases, Odense University Hospital, Odense, Denmark.
Ahmed B MustafaDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Lars ØstergaardDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0000-0003-2459-0511
Fredrikke Dam LarsenDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Lene Surland KnudsenDepartment of Medicine, Zealand University Hospital, Roskilde, Denmark.
Vibeke KlastrupDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Lothar WieseDepartment of Medicine, Zealand University Hospital, Roskilde, Denmark.ORCID https://orcid.org/0000-0003-2719-1743
Thomas BenfieldDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-0698-9385
Kristine Toft PetersenDepartment of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark.
Kasper K IversenDepartment of Cardiology and Department of Emergency Medicine, Herlev-Gentofte Hospital, Herlev, Denmark.
Henrik NielsenDepartment of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark.ORCID https://orcid.org/0000-0002-0841-8255
Joanne ReekieCentre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-8529-3559
Jens LundgrenCentre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-8901-7850
ENFORCE Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Side effects to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are a key concern contributing to vaccine hesitancy, but more individuals may be encouraged if SARS-CoV-2 vaccines were known to lead to a stronger immune response. Methods: Included were adult participants from the Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines (ENFORCE) who completed a questionnaire to assess systemic reactions following SARS-CoV-2 vaccination (BTN162b2, mRNA-1273, ChAdOx1) and had SARS-CoV-2 spike immunoglobulin G (IgG) levels measured at baseline and post-vaccine. A symptom score was developed to measure severity of systemic adverse reactions (+1 for each moderate, +2 for each severe). Post-vaccination SARS-CoV-2 spike IgG levels were compared between participants with different scores using multivariable linear regression. Results: A total of 6528 participants were included (56.3% females; median age [interquartile range], 64 [54-75] years). After the first vaccination, no association was found between symptom score and post-vaccine dose spike IgG level ( Conclusions: An association was found between more severe adverse reactions and stronger antibody response after the second vaccination but not the first, likely attributed to higher levels of preexisting immunity gained from response to first vaccination. Regardless of side effects, most people experienced an effective immune response following vaccination.

Indexed as

adverse drug reactionsantibody responseCOVID-19 vaccinesSARS-CoV-2

Identifiers

PMID37351453
PMCPMC10284342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.